Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA

Gastroenterology

Volumn 125, Issue 1, 2003, Pages 9-18

  Klein, Christian ^a   Bock, C Thomas ^b   Wedemeyer, Heiner ^a   Wüstefeld, Torsten ^a   Locarnini, Stephen ^c   Dienes, Hans Peter ^d   Kubicka, Stefan ^a   Manns, Michael P ^a   Trautwein, Christian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; DOUBLE STRANDED RNA; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NAKED DNA; NUCLEOSIDE ANALOG; VIRUS DNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; HEPATITIS B VIRUS; LIVER CELL; LIVER DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSPORT; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0038449221     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00720-0     Document Type: Article

References (26)

1. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122: 264-273.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34: 1225-1241.
3. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001;120:1000-1008.
4. Marcellin P. Advances in therapy for chronic hepatitis B. Semin Liver Dis 2002;22(suppl 1):33-36.
5. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838.
6. Kock J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsacker F. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001; 75:5084-5089.
7. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-829.
8. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989;59:1145-1156.
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-311.
10. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-747.
11. Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001;8:746-750.
12. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci U S A 1991;88:1059-1063.
13. Bock CT, Malek NP, Tillmann HL, Manns MP, Trautwein C. The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro. J Virol 2000;74:2193-2202.
14. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 2001;121:1158-1166.
15. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000;44:551-560.
16. Rossmanith W, Chabicovsky M, Herkner K, Schulte-Hermann R. Cellular gene dose and kinetics of gene expression in mouse livers transfected by high-volume tail-vein injection of naked DNA. DNA Cell Biol 2002;21:847-853.
17. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002;418:38-39.
18. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-108.
19. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002;418:435-438.
20. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002;418: 430-434.
21. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002;8:681-686.
22. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A 2002;99:13825-13830.
23. Hamilton A, Voinnet O, Chappell L, Baulcombe D. Two classes of short interfering RNA in RNA silencing. EMBO J 2002;21:4671-4679.
24. Kumar M, Carmichael GG. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev 1998;62:1415-1434.
25. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227-264.
26. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.